表阿霉素联合紫杉醇治疗乳腺癌的临床观察  

Clinical observation of paclitaxel combined with epirubicin for treating breast cancer

作　　者：刘磊[1] 李明军[1] 唐小兵[1] 龚勤俭 陈强[1] 

机构地区：[1]安岳县人民医院普外科,四川安岳642350

出　　处：《现代医药卫生》2011年第8期1150-1152,共3页Journal of Modern Medicine & Health

摘　　要：目的:探讨表阿霉素联合紫杉醇化学治疗乳腺癌的疗效及不良反应。方法:用表阿霉素联合紫杉醇治疗Ⅱ、Ⅲ期乳腺癌22例,用表阿霉素50 mg/m2,紫杉醇150 mg/m2治疗3周为1个疗程。所有患者化疗2个周期后行乳腺癌改良根治术,术后继续以原方案化疗4～6个周期。结果:乳腺癌有效率(RR)72.7%(16/22)。无完全缓解病例,16例(72.7%)部分缓解(PR),6例(28.3%)病情稳定(SD),无进展病例(PD)。腋窝肿大淋巴结中45.5%(10/22)化疗后不能触及。主要不良反应为脱发、胃肠道反应、白细胞下降、关节肌肉痛,均可耐受。结论:表阿霉素联合紫杉醇进行乳腺癌化疗是一种安全、有效的方法,能明显缩小乳腺癌的原发肿瘤及腋窝淋巴结转移灶。Objective：To investigate the efficacy and adverse reactions of the chemotherapy of paclitaxel combined with epirubiein in treatment of breast cancer.Methods：22 patients with breast cancer were treated with the combination chemotherapy. Pacllitaxel（150mg/ m2） and epirubiein（50mg/m2） were administered on 1 d in every three weeks as 1 cycle.The efficacy and toxicity were evaluated after two cycles.Results：Among 22 cases, there were no complete response（CR） cases and progressive disease（PD） cases,partial response（PR） in 16 cases（72.7%）,stable disease（SD） in 6 cases（28.3%）. The overall response rate was 72.7%（16/22）.The main adverse effects were myelosuppression, alopecia, vomiting, arthralgia and myalgia and the toxicities were all tolerable.For clinlically involved axillary lymph nodes, 45.5%（10/22） were not palpable after the chemotherapy of paclitaxel and epirubicin.Conclusion：The combination therapy of paclitaxel and epirubicin is safe and effective in the treatment of breast cancer, which can result in shrinkage of primary tumors and axillary lymph nodes in breast cancer.

关 键 词：表阿霉素 紫杉醇 乳腺癌 化疗 

分 类 号：R73[医药卫生—肿瘤]